PARSIPPANY, N.J., Aug. 24, 2016 /PRNewswire/ -- Interpace
Diagnostics Group (NASDAQ: IDXG), a company that provides
clinically useful molecular diagnostic tests and pathology services
for evaluating risk of cancer by leveraging the latest technology
in personalized medicine for better patient diagnosis and
management, reported today that the Company has launched a new
version of their AccuCEA™ product called "Insights" for
Gastroenterologists who focus on diagnosing and treating pancreatic
cancer.
The new AccuCEA Insights service provides physicians for
whom the Company has already provided first line testing, with
additional information on how those results compare to those of
other patients in the Company's proprietary database of over 15,000
patients, thus reporting incremental and valuable information on
the patient's potential molecular profile and overall risk for
developing pancreatic cancer. When the report is delivered to the
ordering physician, they have an opportunity to speak with one of
the Company's expert molecular pathologists and discuss the
potential benefits of conducting a full, molecular pathology review
using PancraGen®, the Company's fully integrated product that
considers all the results from first line testing, imaging,
cytology, and molecular testing and stratifies the patient in one
of 4 risk categories.
Interpace Diagnostics, who has offered their AccuCEA product to
customers for over 5 years, will continue to offer AccuCEA in
addition to AccuCEA Insights. The primary benefit of the
AccuCEA product vs. traditional carcinoembryonic antigen or CEA
testing available from other labs is that AccuCEA is the only CEA
assay that has been validated on small (200uL) amounts of cyst
fluid. Interpace currently performs over 6,000 AccuCEA tests per
year for their customers. CEA is a blood fluid chemistry test
that is commonly done as part of an initial screening performed on
patients suspected of having pancreatic and other types of
cancer. This test, along with other common fluid chemistry
tests like Amylase, may also be referred to as "first line
testing".
"The additional information provided via AccuCEA Insights
provides physicians a more expansive view of their patient's status
and enables them to make an informed decision regarding the most
appropriate next steps," said Interpace President and CEO
Jack Stover. "We believe customers
who currently order first line testing services only will see the
value in not only the incremental information provided via AccuCEA
Insights but the full benefits of our fully integrated
molecular product, PancraGEN."
About PancraGEN®
PancraGEN® is a pancreatic cyst molecular test
that, by using a small sample of pancreatic cyst fluid, can aid in
pancreatic cancer risk assessment. PancraGEN® is
90% accurate, according to clinical studies, enabling effective
risk stratification of patients. Pancreatic cancer is often
difficult to diagnose in early stages and typically spreads rapidly
with signs and symptoms appearing when the cancer is significantly
advanced. Because of this, and that complete surgical removal of
the pancreas is not possible, pancreatic cancer is considered a
leading cause of cancer deaths.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for better patient diagnosis and management. The Company currently
has three commercialized molecular tests: PancraGen® for the
evaluation of pancreatic cysts and assessment of risk of
concomitant or subsequent cancer; ThyGenX®, for the diagnosis
of thyroid cancer from thyroid nodules utilizing a next generation
sequencing assay; and ThyraMIR®, for the diagnosis of thyroid
cancer from thyroid nodules utilizing a proprietary gene expression
assay. Interpace Diagnostics mission is to provide personalized
medicine through molecular diagnostics and innovation to advance
patient care based on rigorous science.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, relating to our future
financial and operating performance. The company has attempted to
identify forward looking statements by terminology including
"believes," "estimates," "anticipates," "expects," "plans,"
"projects," "intends," "potential," "may," "could," "might,"
"will," "should," "approximately" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on
current expectations, assumptions and uncertainties involving
judgments about, among other things, future economic, competitive
and market conditions and future business decisions, all of which
are difficult or impossible to predict accurately and many of which
are beyond company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, our ability to adequately finance the business, our
ability to restructure our debt and other obligations, the market's
acceptance of our molecular diagnostic tests, our ability to secure
additional business and generate higher profit margins through
sales of our molecular diagnostic tests, in-licensing or other
means, projections of future revenues, growth, gross profit and
anticipated internal rate of return on investments. Additionally,
all forward-looking statements are subject to the risk factors
detailed from time to time in the company's periodic filings with
the Securities and Exchange Commission (SEC), including without
limitation, the Annual Report on Form 10-K filed with the SEC on
March 30, 2016, as amended on
April 29, 2016 and June 14, 2016. Because of these and other
risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these
statements speak only as of the date of this press release and,
except as may be required by law, the Company undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
CONTACTS:
Interpace Diagnostics
Investor Relations:
Dave Schemelia
EVC Group, Inc.
(646)201-5431
dave@evcgroup.com
Doug Sherk
EVC Group, Inc.
(646)445-4800
dsherk@evcgroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-launches-new-product-for-pancreatic-cancer-testing-300317473.html
SOURCE Interpace Diagnostics Group, Inc.